OOIR: Observatory of International Research

Papers

(The H4-Index of SLAS Discovery is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones	188
RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery	123
Probing the SAM Binding Site of SARS-CoV-2 Nsp14 In Vitro Using SAM Competitive Inhibitors Guides Developing Selective Bisubstrate Inhibitors	59
High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2	44
Cryo-EM: The Resolution Revolution and Drug Discovery	39
High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids	37
Recommended Guidelines for Developing, Qualifying, and Implementing Complex In Vitro Models (CIVMs) for Drug Discovery	37
High-Throughput Mass Spectrometry for Hit Identification: Current Landscape and Future Perspectives	35
Acoustic Ejection Mass Spectrometry: A Fully Automatable Technology for High-Throughput Screening in Drug Discovery	34
Discovery of Drug-Like Ligands for the Mac1 Domain of SARS-CoV-2 Nsp3	32
In Vitro three-dimensional (3D) cell culture tools for spheroid and organoid models	30
Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry	30
Identification of Compounds for Butyrylcholinesterase Inhibition	29
Using chemical and biological data to predict drug toxicity	29
Selecting Approaches for Hit Identification and Increasing Options by Building the Efficient Discovery of Actionable Chemical Matter from DNA-Encoded Libraries	28
Changing the HTS Paradigm: AI-Driven Iterative Screening for Hit Finding	28
CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle–Dependent Degradation of CDK2	27
Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection	26
Target Validation Using PROTACs: Applying the Four Pillars Framework	26
Identification of potent small molecule inhibitors of SARS-CoV-2 entry	25
A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-19	24
A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19	24
A Tale of Two Tails: Efficient Profiling of Protein Degraders by Specific Functional and Target Engagement Readouts	22
High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics	22
Comparison of Approaches for Determining Bioactivity Hits from High-Dimensional Profiling Data	22

A High-Throughput Radioactivity-Based Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex	22
Validating ADME QSAR Models Using Marketed Drugs	22